Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in pacific asian patients participating in the CRUCIAL trial

Journal of Korean Medical Science

Volumn 28, Issue 12, 2013, Pages 1741-1748

  Cho, Eun Joo ^a   Kim, Jae Hyung ^a   Sutradhar, Santosh ^b   Yunis, Carla ^b   Westergaard, Mogens ^b  

^a The Catholic University of Korea   (South Korea)

^b PFIZER INC   (United States)

Author keywords

Anticholesteremic agents; Antihypertensive agents; Cardiovascular diseases; Clinical trial; Hypertension; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; ASIAN; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICS; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; HYPERTENSION; RISK FACTORS;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84898009834     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.12.1741     Document Type: Article

References (28)

1. Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011; 27: 821-33.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
4. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
5. Lida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S, Tanaka S, Keijnkai T, Horibe H, Minowa M, et al. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese: Nippon data 80. J Hum Hypertens 2003; 17: 851-7.
6. Zhou B, Zhang H, Wu Y, Li Y, Yang J, Zhao L, Zhang X. Ecological analysis of the association between incidence and risk factors of coronary heart disease and stroke in chinese populations. CVD Prevention 1998; 1: 207-16.
7. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-64.
8. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kele-men L, Yi C, Lonn E, Gerstein H, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000; 356: 279-84.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
13. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-7.
14. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
15. NIPPON DATA80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 2006; 70: 1249-55.
16. World Health Organization Regional Offices for South-East Asia and the Western Pacific. Chapter 8: priority noncommunicable diseases and conditions. Health in Asia and the Pacific, 2008.
17. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-8.
18. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
19. Lee HS, Park YM, Kwon HS, Lee JH, Park YJ, Lim SY, Lee SH, Yoon KH, Son HY, Kim DS, et al. Prevalence, awareness, treatment, and control of hypertension among people over 40 years old in a rural area of South Korea: the Chungju Metabolic Disease Cohort (CMC) Study. Clin Exp Hypertens 2010; 32: 166-78.
20. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7.
21. Lenfant C. Reflections on hypertension control rates: a message from the director of the National Heart, Lung, and Blood Institute. Arch Intern Med 2002; 162: 131-2.
22. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17: 631-6.
23. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-45.
24. Steinhagen-Thiessen E, Bramlage P, Lösch C, Hauner H, Schunkert H, Vogt A, Wasem J, Jöckel KH, Moebus S. Dyslipidemia in primary care: prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2008; 7: 31.
25. Lee J, Heng D, Chia KS, Chew SK, Tan BY, Hughes K. Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. Int J Epidemiol 2001; 30: 983-8.
26. Teo KK, Liu L, Chow CK, Wang X, Islam S, Jiang L, Sanderson JE, Rangarajan S, Yusuf S; INTERHEART Investigators in China. Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China Study. Heart 2009; 95: 1857-64.
27. Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, Woodward M. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007; 61: 115-21.
28. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Li Y, Rao X, Zhou B, Detrano R, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 2006; 114: 2217-25.